Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Requirements for FY2005 GE Drug Listing Announced
March 28, 2005
- MONITOR
March 28, 2005
- Receipt of Applications for DMF Started
March 28, 2005
- DIAGNOSTIC NEWS IN BRIEF
March 28, 2005
- Revised GL on Use of Gefitinib Reviewed
March 28, 2005
- MEET THE LEADERS (41)
March 28, 2005
- REGULATORY NEWS IN BRIEF
March 28, 2005
- Overseas Group Companies under Astellas Announced
March 28, 2005
- GL for Package Inserts for Patients in Preparation
March 28, 2005
- Monitor
March 21, 2005
- Early Data Show Significant Antiplatelet Action for Prasugrel: Sankyo
March 21, 2005
- Novo Nordisk Aims at Yearly Growth of 10%: Mr Eilersen
March 21, 2005
- New Study Results on Oral CCR5 Receptor Antagonist Presented: Ono
March 21, 2005
- BULLETIN
March 21, 2005
- Seikagaku to Focus on Joint Diseases, Glycosaminoglycans in R&D
March 21, 2005
- Norvasc Remains No.1 in 4th Qtr: IMS Survey
March 21, 2005
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
March 21, 2005
- Banyu Aiming for Annual Sales of \350 Bil. at Early Date: Mr Hirate
March 21, 2005
- PRESS SEMINAR
March 21, 2005
- Meiji Seika to Enlist Help of MSs in Marketing Activities
March 21, 2005
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…